<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.0 Transitional//EN">
<HTML><HEAD>
<META http-equiv=Content-Type content="text/html; charset=us-ascii"><BASE
href=http://www.femtopizza.net/ head <>
<META content="MSHTML 6.00.2600.0" name=GENERATOR></HEAD>
<BODY text=black bgColor=white>
<DIV>
<DIV class=OutlookMessageHeader dir=ltr align=left><FONT face=Tahoma
size=2></FONT></DIV><FONT face=Arial color=#0000ff size=2></FONT>From the <A
href="http://www.lifelinenutraceuticals.com/">Lifeline Nutraceuticals</A> and <A
href="http://www.ceremedix.com/">Ceremedix</A> websites and mailing lists:
Protandim has now been covered by over 120 media sources stretching all across
the globe. Feature articles in major newspapers, as well as coverage by an NBC
news affiliate and international radio broadcasts. <BR><A
href="http://www.lifelinenutraceuticals.com/">Lifeline Nutraceuticals</A>
(Lifeline) is currently looking to close out its fundraising that is earmarked
for FDA approval processes and product commercialization. Closing has been
delayed due to contractual obligations, but we hope to break escrow by mid
February. Internal and independent product tests have been conducted, but some
of these studies will be repeated for the FDA as soon as the funding is
finalized. Final human trials will also begin at that time. <BR>Lifeline is a
privately held Denver-based nutraceutical licensing and marketing company.
Lifeline has a unique anti-aging nutraceutical, protandim (TM), that acts by
mobilizing the body's own defense and repair mechanisms, resulting in the rescue
of tissues and organs of the body that would otherwise be irrevocably damaged by
the effects of "oxidative stress" caused by aging and numerous diseases.
<BR>Quite a few inquiries have revolved around the publication date of studies
that have already been completed. Lifeline and its affiliate pharmaceutical
company, CereMedix, have intentionally chosen to not publish studies at this
time. <BR><A href="http://www.ceremedix.com/">CereMedix</A>, Inc., is a
privately held Massachusetts-based drug discovery and development company.
CereMedix has a unique portfolio of peptide-based product candidates with the
unique action of activating certain genes present in cells of the human body
that act as the bodys own defend and repair mechanisms. The switching on of
these genes results in the rescue of tissues and organs of the body that would
otherwise be irrevocably damaged by the effects of oxidative stress resulting
from aging and multiple diseases. The company is targeting its therapeutic
products at multi-billion dollar markets with no viable existing
therapeutics.</DIV></BODY></HTML>